Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (April 1991). „Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”. Nature350 (6319): 610–4. DOI:10.1038/350610a0. PMID1840645.
Neve KA, Seamans JK, Trantham-Davidson H (August 2004). „Dopamine receptor signaling”. J. Recept. Signal Transduct. Res.24 (3): 165–205. DOI:10.1081/RRS-200029981. PMID15521361.
Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006). „WAY-100635 is a potent dopamine D4 receptor agonist”. Psychopharmacology (Berl.)188 (2): 244–51. DOI:10.1007/s00213-006-0490-4. PMID16915381.
Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (July 2004). „Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction”. Journal of Medicinal Chemistry47 (15): 3853–64. DOI:10.1021/jm030505a. PMID15239663.
Patel MV, Kolasa T, Mortell K, et al. (December 2006). „Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction”. J. Med. Chem.49 (25): 7450–65. DOI:10.1021/jm060662k. PMID17149874.
Hübner H, Kraxner J, Gmeiner P (2000). „Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments”. J. Med. Chem.43 (23): 4563–9. DOI:10.1021/jm0009989. PMID11087581.
Kolasa T, Matulenko MA, Hakeem AA, et al. (August 2006). „1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction”. J. Med. Chem.49 (17): 5093–109. DOI:10.1021/jm060279f. PMID16913699.
Enguehard-Gueiffier C, Hübner H, El Hakmaoui A, et al. (June 2006). „2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist”. J. Med. Chem.49 (13): 3938–47. DOI:10.1021/jm060166w. PMID16789750.
Nakane M, Cowart MD, Hsieh GC, et al. (July 2005). „2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist”. Neuropharmacology49 (1): 112–21. DOI:10.1016/j.neuropharm.2005.02.004. PMID15992586.
Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P (2008). „Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D4 Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET”. J. Med. Chem.51 (6): 1800–10. DOI:10.1021/jm701375u. PMID18307287.
Kulagowski JJ, Broughton HB, Curtis NR, et al. (May 1996). „3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor”. J. Med. Chem.39 (10): 1941–2. DOI:10.1021/jm9600712. PMID8642550.
Lanig H, Utz W, Gmeiner P (2001). „Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine”. J. Med. Chem.44 (8): 1151–7. DOI:10.1021/jm001055e. PMID11312915.
nih.gov
ncbi.nlm.nih.gov
Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, Civelli O (April 1991). „Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine”. Nature350 (6319): 610–4. DOI:10.1038/350610a0. PMID1840645.
Neve KA, Seamans JK, Trantham-Davidson H (August 2004). „Dopamine receptor signaling”. J. Recept. Signal Transduct. Res.24 (3): 165–205. DOI:10.1081/RRS-200029981. PMID15521361.
Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE (2006). „WAY-100635 is a potent dopamine D4 receptor agonist”. Psychopharmacology (Berl.)188 (2): 244–51. DOI:10.1007/s00213-006-0490-4. PMID16915381.
Cowart M, Latshaw SP, Bhatia P, Daanen JF, Rohde J, Nelson SL, Patel M, Kolasa T, Nakane M, Uchic ME, Miller LN, Terranova MA, Chang R, Donnelly-Roberts DL, Namovic MT, Hollingsworth PR, Martino BR, Lynch JJ, Sullivan JP, Hsieh GC, Moreland RB, Brioni JD, Stewart AO (July 2004). „Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction”. Journal of Medicinal Chemistry47 (15): 3853–64. DOI:10.1021/jm030505a. PMID15239663.
Patel MV, Kolasa T, Mortell K, et al. (December 2006). „Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction”. J. Med. Chem.49 (25): 7450–65. DOI:10.1021/jm060662k. PMID17149874.
Hübner H, Kraxner J, Gmeiner P (2000). „Cyanoindole derivatives as highly selective dopamine D4 receptor partial agonists: solid-phase synthesis, binding assays, and functional experiments”. J. Med. Chem.43 (23): 4563–9. DOI:10.1021/jm0009989. PMID11087581.
Kolasa T, Matulenko MA, Hakeem AA, et al. (August 2006). „1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction”. J. Med. Chem.49 (17): 5093–109. DOI:10.1021/jm060279f. PMID16913699.
Enguehard-Gueiffier C, Hübner H, El Hakmaoui A, et al. (June 2006). „2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist”. J. Med. Chem.49 (13): 3938–47. DOI:10.1021/jm060166w. PMID16789750.
Nakane M, Cowart MD, Hsieh GC, et al. (July 2005). „2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist”. Neuropharmacology49 (1): 112–21. DOI:10.1016/j.neuropharm.2005.02.004. PMID15992586.
Prante O, Tietze R, Hocke C, Löber S, Hübner H, Kuwert T, Gmeiner P (2008). „Synthesis, Radiofluorination, and In Vitro Evaluation of Pyrazolo[1,5-a]pyridine-Based Dopamine D4 Receptor Ligands: Discovery of an Inverse Agonist Radioligand for PET”. J. Med. Chem.51 (6): 1800–10. DOI:10.1021/jm701375u. PMID18307287.
Kulagowski JJ, Broughton HB, Curtis NR, et al. (May 1996). „3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor”. J. Med. Chem.39 (10): 1941–2. DOI:10.1021/jm9600712. PMID8642550.